மைய மிச்சிகன் பல்கலைக்கழகம் கல்லூரி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மைய மிச்சிகன் பல்கலைக்கழகம் கல்லூரி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மைய மிச்சிகன் பல்கலைக்கழகம் கல்லூரி Today - Breaking & Trending Today

Cassandra Vogel joins Spectrum Health OB/GYN team

Parents concerned about vaccinating kids against COVID-19


More Americans are expected to soon be eligible to receive the Pfizer vaccine after the FDA gave an emergency use authorization to begin administering the vaccine to kids ages 12 to 15-years-old.
More Americans are expected to soon be eligible to receive the Pfizer vaccine after the FDA gave an emergency use authorization to begin administering the vaccine to kids ages 12 to 15-years-old.
“She will not be first in line to get it,” said Laurie Aguirre, Sanford mother.
Aguirre has a 13-year-old daughter and she said it is just too soon.
“We’re not the anti-vaxxers. We do get vaccines. I’m just not going to have my kids be guinea pigs and part of some giant experiment,” Aguirre said. ....

United States , Laurie Aguirre , Nicholas Haddad , Central Michigan University College Of Medicine , More Americans , Central Michigan University College , ஒன்றுபட்டது மாநிலங்களில் , நிக்கோலஸ் ஹடாட் , மைய மிச்சிகன் பல்கலைக்கழகம் கல்லூரி ஆஃப் மருந்து , மேலும் அமெரிக்கர்கள் , மைய மிச்சிகன் பல்கலைக்கழகம் கல்லூரி ,

Clinical trial says Pfizer vaccine protection lasts for 6 months


An ongoing phase three clinical trial of Pfizer-Biontech s coronavirus vaccine is confirming the protection lasts at least six months after the second dose.
An ongoing phase three clinical trial of Pfizer-Biontech s coronavirus vaccine is confirming the protection lasts at least six months after the second dose.
“This is great news that puts into numbers what we ve been expecting. The Pfizer from the beginning and both MRNA vaccines, messenger RNA vaccines. So, Pfizer and Moderna have had really very robust responses in individuals who got the vaccine,” said Infectious Disease Specialist with Central Michigan University College of Medicine Nicholas Haddad.
The vaccine remains more than 91% effective against COVID-19 for six months. The vaccine appears to be fully effective against the South Africa variant, the dominant virus strain circulating, and the one researcher s fear has evolved to evade the vaccines. ....

South Africa , Infectious Disease Specialist , Central Michigan University College , Medicine Nicholas , தொற்று நோய் நிபுணர் , மைய மிச்சிகன் பல்கலைக்கழகம் கல்லூரி , மருந்து நிக்கோலஸ் ,